<DOC>
	<DOCNO>NCT00377923</DOCNO>
	<brief_summary>This multiple dose , observer blind , randomise , parallel group pharmacodynamic pharmacokinetic study assess endometrial effect ( predecidual change ) new aqueous progesterone formulation administer s.c. dose 25 50 mg/day .</brief_summary>
	<brief_title>Endometrial Effects Daily Progesterone s.c. 25 50 Mg Aqueous Formulation Female Healthy Volunteers</brief_title>
	<detailed_description>This study design order ass efficacy investigational product ( Progesterone acqueous s.c. formulation ) administer dose 25 50 mg . The induced predecidual change evaluate endometrial bioptic sampling , perform day 11 compare two treatment group . The pharmacokinetic evaluation design accord internationally recognise guideline PK study .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>BMI : 19 &lt; /=BMI &lt; /=25 kg/m2 ; Proper estrogen priming ; absence progesterone exposure prior exogenous progesterone administration ; normal pelvic ultrasound ; absence active follicular growth follow initiation E2 treatment ; Complete suppression ovarian function ; Vital sign : SBP 100139 mmHg , DBP 5089 , HR 5090 bpm ; Full comprehension nature purpose study possible risk side effect ; sign write informed consent prior inclusion study pregnant lactating woman ; ECG : clinically relevant abnormality ; clinical relevant abnormal physical finding could interfere objective study ; clinical relevant abnormal laboratory value indicative physical illness , ascertain presumptive hypersensitivity active principle and/or formulation ' ingredient ; history anaphylaxis drug allergic reaction general , Investigator considers may affect outcome study ; history uterine pathology ( fibroid , polyp , adenomyosis , etc ) , history dysfunctional bleeding , relevant history renal , hepatic , cardiovascular , respiratory , skin , haematological , endocrine neurological disease , history neoplasia ( genital apparatus , breast , liver hormonedependent cancer ) severe liver failure , acute chronic liver dysfunction , cholestatic jaundice , hypertension , thrombophlebitis , thromboembolism , cerebrovascular insult severe depression ; medication , include OTC , 2 week start study ; participation evaluation drug within 1 month prior start study ; blood donation 1 month prior study ; history drug , alcohol [ &gt; 1 drink/day define accord USDA Dietary Guidelines 2005 ( 18 ) ] caffeine ( &gt; 5 cups/ day coffee tea ) tobacco abuse ( â‰¥10 cigarettes/day ) ; Abnormal diet ( &lt; 1600 &gt; 3500 kcal/day ) substantial change eat habit within past 4 week .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>pharmacodynamic pharmacokinetic study</keyword>
	<keyword>Progesterone</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>Endometrial decidualisation</keyword>
</DOC>